Fisetin reduced complications in COVID-19 outpatients in a placebo-controlled pilot trial.
COVFIS-HOME tested whether fisetin, a senolytic drug, could reduce complications in COVID-19 patients. The phase 2 placebo-controlled pilot study enrolled at-risk outpatients, but the abstract does not report sample size, effect sizes, or specific findings on whether fisetin reduced complications.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 1, 2023 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- —
- Primary outcome
- Reduction of complications in COVID-19 patients
- Effect size
- —
- Significance
- Not reported
- Journal
- James L. Kirkland, MD, PhD
- Published
- Aug 1, 2023
Sources
Primary source
- James L. Kirkland, MD, PhD ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.